With its new code of conduct, the Association Innovative Medicines (Vereniging Innovatieve Geneesmiddelen (VIG)) – the industry association for the Dutch branches of innovative pharmaceutical companies – has failed to set out a moral compass that answers urgent societal questions regarding high medicine prices and the pharmaceutical industry. This is Wemos’ main message in a first reaction to the new code of conduct, which has been published today.
Wemos applauds the fact that the VIG has invested in this new code of conduct. “In recent, years, the pharmaceutical sector has received much negative media attention due to cases of extremely high prices of new medicines and inexplicable price hikes. A new code of conduct would and should improve the sector’s moral status. And yet, we think this new code is a missed opportunity”, says global health advocate Tom Buis.
Read the (full) Dutch article here.